November 14, 2006

FDC LIMITED and AKORN INC, USA, sign exclusive development and Supply Agreement for Two Ophthalmic Suspensions drug Products.

FDC Limited and Akorn Inc., a leading marketing Company for Ophthalmic drugs in the United States, have signed an exclusive development and supply agreement for two Ophthalmic suspension drug products. The two drugs currently have a combined United States market size of approximately $170 million. Under the terms of the agreement, FDC will fund the development and be responsible for manufacturing the two Ophthalmic suspensions. Akorn will be responsible for marketing the two drugs in the United States and will receive 40% of the gross profit, while FDC will receive 60% of the gross profit generated from sales of the two drugs. FDC will own the ANDAs and Akorn has agreed to meet the annual minimum unit sales requirements in order to maintain United States marketing exclusivity.

Mr. Arthur S. Przbyl, President and CEO of Akorn has stated, “This Agreement further strengthens our increasing partnership with FDC. We remain impressed with FDC's blow- fill- seal technology and its use in ophthalmic products. We have filed two ANDAs this year for FDC and look forward to several more”.

Mr. Nandan Chandavarkar, Jt. Managing Director of FDC, has stated “FDC is excited about working with Akorn on these suspension Products. We believe that our strong product development and manufacturing capabilities are very well complemented by Akron's strengths in sales and marketing.”